Patent · US Active

Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders

US12209144B2 · kind B2 · utility

0Cited by

5References

1Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Alec Nathanson Flyer · Cambridge, US
Andrei Golosov · Cambridge, US
Philipp Grosche · Inzlingen, DE
Ian Lewis · Riehen, CH
Eugene Yuejin Liu · Lexington, US
Andreas Marzinzik · Weil, DE
Lauren G. Monovich · Summit, US
Johannes Ottl · Lörrach, DE
Tajesh Jayprakash Patel · Medford, US
Patrick Reid · Tokyo, JP
Mohindra Seepersaud · Cambridge, US

Key dates

Filing date	Nov 26, 2019
Grant date	Jan 28, 2025
Priority date	—
Expiry date	Dec 9, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I):

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.